Xolair 150 MG/ML autoinjectorml
Ended Awarded
- Contract number
- SPE2DB25FCMXS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,712
Award facts
- Contract value 100% obligated
- $1,712.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,712.22 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml auto-injector on August 13, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order was issued under the SPE2DB Indefinite Delivery Contract (IDC), a $500 million single-award vehicle that enables DLA to procure pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide. The award carries no set-aside designation, and DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its facility location.
XOLAIR (omalizumab) is a biologic medication used primarily for severe asthma and chronic idiopathic urticaria management. As a well-established supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group leverages its status as a woman-owned small business to compete effectively for delivery orders across DLA's extensive pharmaceutical portfolio, which encompasses branded and generic prescription drugs, biologics, over-the-counter medications, and specialty medical consumables supporting military health operations globally. This delivery order represents a routine procurement transaction through the company's established IDC relationship with DLA.
Quick answers
Who was awarded contract SPE2DB25FCMXS?
SPE2DB25FCMXS was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 13, 2025.
How much is contract SPE2DB25FCMXS worth?
The government has obligated $1,712 on SPE2DB25FCMXS.
Is contract SPE2DB25FCMXS an order under another contract?
Yes. SPE2DB25FCMXS is a delivery order under SPE2DB24D9144, an indefinite delivery contract.
Was contract SPE2DB25FCMXS competed?
The extent of competition for SPE2DB25FCMXS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award